Some statistically significant differences between citalopram and other antidepressants for the acute phase treatment of major depression were found in terms of efficacy , tolerability and acceptability .
Citalopram was more efficacious than paroxetine and reboxetine and more acceptable than tricyclics , reboxetine and venlafaxine , however , it seemed to be less efficacious than escitalopram .
BACKGROUND Recent US and UK clinical practice guidelines recommend that second-generation antidepressants should be considered amongst the best first-line options when drug therapy is indicated for a depressive episode .
Systematic review s have already highlighted some differences in efficacy between second-generation antidepressants .
Citalopram , one of the first selective serotonin reuptake inhibitors ( SSRI ) introduced in the market , is one of these antidepressant drugs that clinicians use for routine depression care .
OBJECTIVES To assess the evidence for the efficacy , acceptability and tolerability of citalopram in comparison with tricyclics , heterocyclics , other SSRIs and other conventional and non-conventional antidepressants in the acute-phase treatment of major depression .
MRI subcortical hyperintensities in old and very old depressed outpatients: The important role of age in late-life depression
OBJECTIVE There is increasing evidence that cerebrovascular factors play a key role in the etiology of  late-life depression .  This study examined the severity of subcortical hyperintensities ( SH ) and the relationship between SH and depression characteristics in two sample s of elderly depressed out patients differing in age . METHODS The sample s consisted of 59 subjects age 60 and over , ( 69+/-5.6 years ) , who participated in a trial of sertraline , and 111 subjects age 75 and over , ( 79+/-4.1 years ) , who participated in a trial of citalopram .  RESULTS The citalopram group was significantly older than the sertraline group and had more severe SH ( 72 % vs. 42 % high ratings ) . The High SH group was significantly older than the Low SH group in the sertraline study but there was no difference in age in the SH groups in the citalopram sample . There was no relationship between SH severity and baseline depression or age of onset . However , age strongly correlated with later age of onset . There was no relationship between SH severity and cardiovascular risk factors or treatment response in the sertraline sample . CONCLUSION Age is a major factor for the development of SH and late-life depression . There may not be an association between SH and depression severity , cardiovascular risk factors , or treatment response in geriatric depressed out patients . The etiologic factors and clinical course of late-life depression requires further study
Some statistically significant differences between citalopram and other antidepressants for the acute phase treatment of major depression were found in terms of efficacy , tolerability and acceptability .
Citalopram was more efficacious than paroxetine and reboxetine and more acceptable than tricyclics , reboxetine and venlafaxine , however , it seemed to be less efficacious than escitalopram .
BACKGROUND Recent US and UK clinical practice guidelines recommend that second-generation antidepressants should be considered amongst the best first-line options when drug therapy is indicated for a depressive episode .
Systematic review s have already highlighted some differences in efficacy between second-generation antidepressants .
Citalopram , one of the first selective serotonin reuptake inhibitors ( SSRI ) introduced in the market , is one of these antidepressant drugs that clinicians use for routine depression care .
OBJECTIVES To assess the evidence for the efficacy , acceptability and tolerability of citalopram in comparison with tricyclics , heterocyclics , other SSRIs and other conventional and non-conventional antidepressants in the acute-phase treatment of major depression .